RE:RE:RE:ONCY presents 2 posters at ASCO 2024In December 2023 ONCY presented results at the San Antonio Breast Cancer Symposium (SABC) that further supported the ASCO 2024 study results which demonstrated that patients treated with chemotherapy and atezolizumab, an anti-PD-L1 therapy, and intravenous treatment with pela (pelareorep), the total, new and pre-existing blood TIL expanded.
These separate results have confirmed the previously reported CelTIL results from AWARE-1 demonstrating pelareorep induced increases in TILs post pelareorep+atezolizumab+chemotherapy treatment.
https://oncolyticsbiotech.com/wp-content/uploads/2023/12/SABC-2023-AWARE-TIL-Expansion_Final_TH.pdf
https://oncolyticsbiotech.com/media/